DUSP1 and prostate carcinoma: The study further pointed out that overexpression of DUSP1 can control/reverse USP33 knockdown-induced JNK activation and cell apoptosis in docetaxel-treated prostate cancer cells, suggesting that USP33 overexpression in prostate cancer stabilized DUSP1 (by de-ubiquitination) and may contribute to docetaxel resistance.84